World / Eyesight Disorders
06.09.2008 04:12
medicalnewstoday.com
SARcode Corporation, a private company focused on small molecule LFA-1 inhibitors to treat inflammatory diseases, and Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced SARcode's initiation of a Phase 1 clinical trial of a small molecule LFA-1 product candidate for T-cell mediated ophthalmic diseases.
World
Eyesight Disorders
06.09.2008 04:12
medicalnewstoday.com
Electronic fingerprinting, iris scans, and signature recognition software are all becoming commonplace biometrics for user authentication and security. However, they all suffer from one major drawback - they can be spoofed by a sufficiently sophisticated intruder. Writing in the International Journal of Biometrics, Japanese researchers describe a new approach based on a person's reflexes that could never be copied, forged, or spoofed.
World
Eyesight Disorders
English
Українська
Русский
Date: 03 December 2008 - 14:15
Number of sources in English: 130